Catalyst Biosciences Inc
F:HGF2
Operating Margin
Catalyst Biosciences Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
C
|
Catalyst Biosciences Inc
F:HGF2
|
279.6m EUR |
-3 704%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
330.5B USD |
30%
|
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
164.4B USD |
25%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
137.2B USD |
38%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.8B USD |
38%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
127.5B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.7B USD |
29%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Catalyst Biosciences Inc
Glance View
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2006-04-12. The firm is focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system or where complement components are associated with the progression of the disease state. Its pipeline consists of a preclinical complement component 3 (C3) degrader program for geographic atrophy (GA) in dry age-related macular degeneration (dAMD), an improved Complement Factor I (CFI) protease, CB 4332, for subcutaneous (SQ) or intravitreal (IVT) therapy to restore complement homeostasis in diseases of overactive complement or CFI deficiencies, and proteases from our ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways. The Company’s portfolio consists of development candidates, which include CB 4332 and CB 2782-PEG.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Catalyst Biosciences Inc's most recent financial statements, the company has Operating Margin of -3 703.7%.